[HTML][HTML] Targeting the NLRP3 inflammasome in severe COVID-19
TL Freeman, TH Swartz�- Frontiers in immunology, 2020 - frontiersin.org
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a member of the genus
Betacoronavirus within the family Coronaviridae. It is an enveloped single-stranded positive�…
Betacoronavirus within the family Coronaviridae. It is an enveloped single-stranded positive�…
[HTML][HTML] The possible pathophysiology mechanism of cytokine storm in elderly adults with COVID-19 infection: the contribution of “inflame-aging”
Abstract Purpose Novel Coronavirus disease 2019 (COVID-19), is an acute respiratory
distress syndrome (ARDS), which is emerged in Wuhan, and recently become worldwide�…
distress syndrome (ARDS), which is emerged in Wuhan, and recently become worldwide�…
Effect of hydroxychloroquine on clinical status at 14 days in hospitalized patients with COVID-19: a randomized clinical trial
Importance Data on the efficacy of hydroxychloroquine for the treatment of coronavirus
disease 2019 (COVID-19) are needed. Objective To determine whether hydroxychloroquine�…
disease 2019 (COVID-19) are needed. Objective To determine whether hydroxychloroquine�…
[HTML][HTML] Diagnostic and prognostic value of hematological and immunological markers in COVID-19 infection: A meta-analysis of 6320 patients
Objective Evidence-based characterization of the diagnostic and prognostic value of the
hematological and immunological markers related to the epidemic of Coronavirus Disease�…
hematological and immunological markers related to the epidemic of Coronavirus Disease�…
[HTML][HTML] Comparison of nonhuman primates identified the suitable model for COVID-19
S Lu, Y Zhao, W Yu, Y Yang, J Gao, J Wang…�- Signal transduction and�…, 2020 - nature.com
Identification of a suitable nonhuman primate (NHP) model of COVID-19 remains
challenging. Here, we characterized severe acute respiratory syndrome coronavirus 2�…
challenging. Here, we characterized severe acute respiratory syndrome coronavirus 2�…
[HTML][HTML] SARS-CoV-2/COVID-19: viral genomics, epidemiology, vaccines, and therapeutic interventions
The COVID-19 pandemic is due to infection caused by the novel SARS-CoV-2 virus that
impacts the lower respiratory tract. The spectrum of symptoms ranges from asymptomatic�…
impacts the lower respiratory tract. The spectrum of symptoms ranges from asymptomatic�…
[HTML][HTML] The role of micronutrients in support of the immune response against viral infections
F Pecora, F Persico, A Argentiero, C Neglia, S Esposito�- Nutrients, 2020 - mdpi.com
Viral infections are a leading cause of morbidity and mortality worldwide, and the importance
of public health practices including handwashing and vaccinations in reducing their spread�…
of public health practices including handwashing and vaccinations in reducing their spread�…
Invasive pulmonary aspergillosis in the COVID‐19 era: An expected new entity
M Machado, M Valerio, A �lvarez‐Ur�a, M Olmedo…�- Mycoses, 2021 - Wiley Online Library
Objectives Information on the recently COVID‐19‐associated pulmonary aspergillosis
(CAPA) entity is scarce. We describe eight CAPA patients, compare them to colonised ICU�…
(CAPA) entity is scarce. We describe eight CAPA patients, compare them to colonised ICU�…
[HTML][HTML] COVID-19 in cancer patients: risk, clinical features, and management
C Liu, Y Zhao, D Okwan-Duodu, R Basho…�- Cancer biology &�…, 2020 - ncbi.nlm.nih.gov
A novel coronavirus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2) has spread across the world, prompting the World Health Organization to declare the�…
2) has spread across the world, prompting the World Health Organization to declare the�…
Tocilizumab for severe COVID-19: a systematic review and meta-analysis
SH Lan, CC Lai, HT Huang, SP Chang, LC Lu…�- International journal of�…, 2020 - Elsevier
This systemic review and meta-analysis aimed to assess the efficacy of tocilizumab for the
treatment of severe coronavirus disease 2019 (COVID-19). Candidate studies up to 24 May�…
treatment of severe coronavirus disease 2019 (COVID-19). Candidate studies up to 24 May�…